Criss, S. D., Mooradian, M. J., Sheehan, D. F., Zubiri, L., Lumish, M. A., Gainor, J. F., . . . Kong, C. Y. (2018). Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncol.

Criss, Steven D., Meghan J. Mooradian, Deirdre F. Sheehan, Leyre Zubiri, Melissa A. Lumish, Justin F. Gainor, Kerry L. Reynolds, und Chung Yin Kong. "Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy Vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System." JAMA Oncol 2018.

Criss, Steven D., et al. "Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy Vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System." JAMA Oncol 2018.